Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels

BACKGROUND: In the trial of Minocycline in Clinically Isolated Syndrome (MinoCIS), minocycline significantly reduced the risk of conversion to clinically definite multiple sclerosis (CDMS). Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are emerging biomarkers in MS, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Camara-Lemarroy, Carlos, Metz, Luanne, Kuhle, Jens, Leppert, David, Willemse, Eline, Li, David KB, Traboulsee, Anthony, Greenfield, Jamie, Cerchiaro, Graziela, Silva, Claudia, Yong, V Wee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574233/
https://www.ncbi.nlm.nih.gov/pubmed/35848622
http://dx.doi.org/10.1177/13524585221109761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574233/
https://www.ncbi.nlm.nih.gov/pubmed/35848622
http://dx.doi.org/10.1177/13524585221109761

Ejemplares similares